VNVidya Navaratnam

Vidya Navaratnam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vidya Navaratnam has a total of 325 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ambient Air Pollution, Climate, Land Use, and Small-Area Incidence of Interstitial Lung Disease: A Bi-National Semi-Ecological Study

    by Cheng Zhao, Gillian C. Goobie, Caitlin C. Fermoyle, Doris Lan, Joseph Van Buskirk, Jeremy P Wrobel, Lauren K Troy, Ian Glaspole, Margaret Wilsher, Sally de Boer, et al.

  • Open Access

    End of rarity: the evolving burden of interstitial lung diseases in England – trends from a national population-based cohort study

    by Georgie May Massen, Ann Dorothy Morgan, Peter M George, Jennifer K Quint, Vidya Navaratnam

    Background: The disease burden from interstitial lung diseases (ILDs) is thought to be increasing globally, but there is a paucity of data on epidemiological trends in non-idiopathic pulmonary fibrosis (IPF) ILD. We calculated incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD in England from 2005 to 2022 and investigated trends over time. Methods: Using linked primary and secondary electronic healthcare records, we used three code-based algorithms to estimate incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD subtypes. We additionally stratified our results by sex, age-group and region. Poisson regression was used to investigate changes to trends over time. We used Kaplan-Meier methods to calculate median survival. Results: There were 153 975 incident cases of ILD in either primary or secondary care records. Incidence rates of all ILD, IPF and non-IPF ILD were 30% higher in 2022 compared with 2005, with rates plateauing from 2018 onwards. The prevalence of IPF and non-IPF ILD increased by 6% and 7%, respectively, over the study period. Mortality rates adjusted for age and sex in people with all ILD and non-IPF ILD were similar in 2022 compared with 2005 but in people with IPF it was 15% lower. Median survival of our overall ILD cohort was 5.4 years (IQR 1.88–13.03). Conclusions: Our population-based study highlights that ILD are no longer rare. Currently, there are 200 000 people living with ILD and 60 000 new cases are diagnosed each year. Healthcare and research funding needs to reflect this growing burden.

  • Open Access

    Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry

    by Michelle Chee, Yet Hong Khor, Dan Jackson, Wendy Cooper, Jason D’COsta, Sally de Boer, Adrienne Edwards, Samantha Ellis, Eli Gabbay, Henry Gallagher, et al.

    Background and aims: Real‐world evaluation of clinical characteristics and treatment profile of patients with idiopathic pulmonary fibrosis (IPF) is needed to establish areas for improvement according to evidence‐based recommendations. This study evaluated the clinical characteristics and treatment profile of patients with IPF from the Australasian ILD Registry (AILDR), comparing them to the Australian IPF Registry (AIPFR) cohort, to identify differences in baseline characteristics among IPF patients treated with antifibrotics and immunosuppressants. Methods: Consecutive patients with IPF enrolled between May 2016 and December 2023 from the AILDR and data of patients enrolled in the AIPFR between 2012 and 2016 were included. Results: A total of 842 and 647 patients with IPF were included from the AILDR and the AIPFR respectively. Both cohorts were male predominant (AILDR: 72.0%; AIPFR: 67.7%) of similar mean body mass index (AILDR: 29.2 ± 4.9 kg/m 2 ; AIPFR: 28.7 ± 4.8 kg/m 2 ). With regard to disease‐targeted treatment, 572 (67.9%) and 108 (12.8%) participants of the AILDR cohort were on antifibrotic medications and immunosuppressants respectively. There were a total of 35.6% ( n = 300) IPF patients on pirfenidone and 40.4% ( n = 340) on nintedanib in AILDR. Only 146 (23%) of the AIPFR cohort were receiving antifibrotics. Of newly registered patients in 2016 (n = 18), 2020 ( n = 71) and 2023 ( n = 151), 50.0%, 18.3% and 15.2% respectively had received immunosuppressive therapy. Conclusion: Baseline demographics from the IPF cohorts for both AILDR and AIPFR are largely comparable, with increasing antifibrotic and decreasing use of immunosuppressants since 2016. Immunosuppressive therapy in IPF remains relatively higher than expected despite guideline recommendations.

  • Open Access

    Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets

    by Daniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, Beatriz Guillen-Guio, Olivia C. Leavy, Ayodeji Adegunsoye, Helen L. Booth, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, William A. Fahy, Tasha E. Fingerlin, et al.

    Extract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease thought to result from an aberrant response to lung injury, culminating in an exaggerated healing response with excessive deposition of extracellular matrix in the interstitium [1].


  • Open Access

    Deep‐Learning Algorithm Diagnostic Support for Usual Interstitial Pneumonia Pattern Recognition in Fibrotic Interstitial Lung Disease

    by Caitlin C Fermoyle, John A Mackintosh, Vidya Navaratnam, Samantha J Ellis, Wendy A Cooper, Nicole S L Goh, Yuben Moodley, Paul N Reynolds, Christopher J Zappala, Peter Hopkins, et al.

    Background and Objective: High resolution computed tomography (HRCT) scan diagnostic classification for usual interstitial pneumonia (UIP) plays a critical role in therapeutic decision‐making and clinical trial eligibility for interstitial lung disease (ILD) patients, but is subject to variability. A deep learning algorithm, the Systematic Objective Fibrotic Imaging Analysis Algorithm (SOFIA), has been validated to assist classification of HRCTs based on current guidelines. In this study, we evaluate the impact of SOFIA on inter‐observer agreement for UIP classification and prognostic accuracy of clinicians' assessment of ILD HRCTs. Methods: Radiologists and pulmonologists (reviewers) were invited to evaluate 203 HRCTs from a national fibrotic ILD registry, scoring each of four UIP categories (definite UIP, probable UIP, indeterminate, or alternative diagnosis). SOFIA outputs were then provided, and reviewers were able to reevaluate their scores. Changes in interobserver agreement for UIP classification and prognostic accuracy were calculated. Results: Three hundred twelve reviewers (120 radiologists, 192 pulmonologists) from 49 countries evaluated 203 HRCT scans. Following SOFIA, inter‐observer diagnostic agreement improved for definite UIP from moderate to good (ICC pre = 0.54[0.50–0.60]; ICC post = 0.70[0.66–0.74]), and for probable UIP from fair to moderate (ICC pre = 0.30[0.27–0.35]; ICC post = 0.53[0.49–0.58]). Following SOFIA, there was improved prognostic accuracy for reviewers' definite UIP, probable UIP, and indeterminate scores (significant change in c‐index), and the proportion of reviewers whose probable UIP scores were significantly predictive of transplant‐free survival increased by 42%. Conclusion: Providing SOFIA algorithm output to clinicians reviewing HRCT scans improved diagnostic agreement and prognostic accuracy for fibrotic ILD. SOFIA may be a useful automated assistive tool to support improved diagnostic consistency.


  • Open Access

    Prescribing trends and environmental impact of prescribed inhaled medicines in Australia

    by Sharon W. L. Lam, Vidya V. Navaratnam, Danielle F. Wurzel, Brett Montgomery, John D. Blakey

    Pressurised metered dose inhalers (pMDIs) release greenhouse gases with substantially higher carbon dioxide equivalent (CO 2 e) emission than other inhalers. Data from the Pharmaceutical Benefits Scheme (PBS) from 2013-2023, showed 28.3% increase in inhalers prescribed. pMDIs account for 47.5% of inhalers prescribed, contributing to 95.6 of inhaler-related carbon emissions. Targeted strategies to optimise disease control and promote use of non-pMDI inhalers where clinically appropriate can significantly reduce emissions while maintaining high-quality care.

  • Open Access

    Lung Cancer in interstitial lung disease: a matched case-control and cohort analysis

    by Megan Harrison, Vidya Navaratnam, Francesca Gonnelli, Caitlin Fermoyle, David Price, Richard Hubbard, Tamera J. Corte

    Background: Lung cancer is significantly more common in patients with idiopathic pulmonary fibrosis (IPF) than the general population. Whether this risk extends to other fibrotic interstitial lung diseases (ILDs) including hypersensitivity pneumonitis (HP) and connective-tissue disease ILD (CTD-ILD), remains uncertain. We aimed to characterise lung cancer prevalence and incidence across ILDs. Methods: We conducted matched case-control and cohort analyses using the Optimum Patient Care Research Database. Adults with incident ILD were matched up to 1:4 to controls by age, sex, and practice. Pre-existing lung cancer was examined using conditional logistic regression. Lung cancer incidence rates were analysed using Fine–Gray competing-risk models. Analyses were conducted overall and by ILD subtype. Findings: We evaluated 15 777 people with ILD (10 030 IPF, 4347 CTD-ILD, 1400 HP) and 62 417 controls. Prevalence of lung cancer at index date was 1.3% in ILD versus 0.4% in controls (OR 2.68; 95%CI 2.21–3.23). During follow-up (median 3.0 years, IQR 1.3–5.4), 540 (3.5%) ILD cases and 790 (1.3%) controls developed lung cancer. The incidence rate was 963.43 in ILD versus 367.57 in controls per 100 000 person-years with sub-distributional hazard ratio (sHR) of 1.93 (95%CI 1.72–2.17). Lung cancer risk was elevated in cases with IPF (sHR 2.36, 95%CI 2.08–2.69) and CTD-ILD (sHR 1.78, 95%CI 1.48–2.14) but not HP. Findings were consistent in never-smokers. Interpretation: A strong relationship between ILD and lung cancer exists, with increased risk in CTD-ILD and IPF compared to the general population. Findings of this study support consideration of targeted lung-cancer surveillance within ILD management paradigms.

  • The increasing burden of bronchiectasis in the UK

    by Eleni Bacopanos, Douglas L. Forrester, Ella Girdler, Francesca Gonnelli, Jennifer K. Quint, Vidya Navaratnam


  • The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study

    by Francesca Gonnelli, Heath Heatley, Ursie Smith, Neva Eleangovan, Vidya Navarantam, John Townend, Tamera J. Corte, David B. Price, Victoria Carter, Martina Bonifazi, et al.

  • Open Access

    Loeys‐Dietz Syndrome and Asthma: Pathophysiological Insights and Clinical Dilemmas

    by Ella Brockwell‐Mole, John D. Blakey, Vidya V. Navaratnam

    A 23‐year‐old man presented with a life‐threatening asthma exacerbation following a respiratory infection. Although he had a childhood history of asthma, he had remained asymptomatic in adulthood and reported regular use of both vapes and marijuana. His medical history included Type 2 Loeys‐Dietz syndrome (LDS), requiring multiple vascular surgeries, rendering standard asthma therapies relatively contraindicated. Due to the severity of his condition, nebulised beta‐agonists were cautiously administered, and his beta‐blocker therapy was substituted. Imaging and forced oscillation technique (FOT) demonstrated severe obstructive airways disease. Marked and persistent eosinophilia was noted. While asthma is a recognised comorbidity in LDS, earlier recognition and intervention, such as inhaled corticosteroids, smoking cessation support, and judicious use of beta‐blockers, may have reduced the severity. Increased awareness of the prevalence and severity of asthma in LDS could support earlier diagnosis, preventive strategies and timely escalation of therapy, thereby reducing the risk of catastrophic respiratory events.